Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
FRIENDSWOOD, Texas, August 08, 2022--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2022.
FRIENDSWOOD, Texas, August 04, 2022--Castle announced that the AGA published an update article stating that TissueCypher® may be beneficial for risk-stratification of patients with NDBE.